Bottom line
RXL vs JDOC: the short answer
RXL (ProShares Ultra Health Care) and JDOC (JPMorgan Healthcare Leaders ETF) share a meaningful slice of their top holdings — about 51% by weight.
JDOC is cheaper at 0.65% vs 0.95% — a difference of $30 a year per $10,000 invested.
Over one year, RXL returned +19.7% vs +14.9% for JDOC.
Updated Nov 19, 2026
RXL vs JDOC side by side
| RXL | JDOC | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | ProShares | J.P. Morgan |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.95% | 0.65% |
| Annual cost per $10k | $95 | $65 |
| 10-yr cost on $10k (prospectus) | $1,305 | $810 |
| Max front load | None | None |
| 12b-1 fee | — | — |
| 1-yr return | +19.7% | +14.9% |
| 5-yr return (annualized) | +7.2% | — |
| 10-yr return (annualized) | +12.6% | — |
| Best quarter | +29.7% | +11.3% |
| Worst quarter | −28.9% | −11.9% |
| Net assets (fund) | $72.1M | $9.1M |
| Number of holdings | 70 | 61 |
| Portfolio turnover | 4% | 92% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RXL | JDOC | Difference |
|---|---|---|---|
| 2025 | +19.7% | +14.9% | +4.7% |
| 2024 | −2.7% | −0.6% | −2.0% |
Source: Fund prospectus bar charts
Holdings overlap
12 of RXL's top 25 holdings also appear in JDOC's top 25.
| Holding | RXL | JDOC |
|---|---|---|
| Eli Lilly & Co. | 12.67% | 7.76% |
| Johnson & Johnson | 7.86% | 4.82% |
| AbbVie, Inc. | 5.57% | 7.85% |
| UnitedHealth Group, Inc. | 4.98% | 5.85% |
| Merck & Co., Inc. | 4.26% | 4.82% |
| Thermo Fisher Scientific, Inc. | 2.68% | 3.73% |
| Intuitive Surgical, Inc. | 2.18% | 1.93% |
| Abbott Laboratories | 2.15% | 3.11% |
| Bristol-Myers Squibb Co. | 1.68% | 3.57% |
| CVS Health Corp. | 1.67% | 2.83% |
| Danaher Corp. | 1.66% | 2.16% |
| Stryker Corp. | 1.52% | 2.23% |
Source: SEC Form N-PORT
RXL top 10
- Eli Lilly & Co. — 12.67%
- ProShares GENIUS Money Market ETF — 11.81%
- Johnson & Johnson — 7.86%
- AbbVie, Inc. — 5.57%
- UnitedHealth Group, Inc. — 4.98%
- Merck & Co., Inc. — 4.26%
- Repurchase Agreement — 2.91%
- Thermo Fisher Scientific, Inc. — 2.68%
- Amgen, Inc. — 2.62%
- Gilead Sciences, Inc. — 2.41%
JDOC top 10
- AbbVie, Inc. — 7.85%
- Eli Lilly & Co. — 7.76%
- UnitedHealth Group, Inc. — 5.85%
- Merck & Co., Inc. — 4.82%
- Johnson & Johnson — 4.82%
- AstraZeneca plc — 3.76%
- Thermo Fisher Scientific, Inc. — 3.73%
- Bristol-Myers Squibb Co. — 3.57%
- Abbott Laboratories — 3.11%
- CVS Health Corp. — 2.83%
FAQ
What is the difference between RXL and JDOC?
Which is cheaper, RXL or JDOC?
Should I own both RXL and JDOC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.